nach oben

Erschienen in:

10.03.2016 | Hypertonie | Fortbildung

Lösung eines komplexen medizinischen Problems?

Interventionelle Verfahren bei therapieresistenter Hypertonie

verfasst von: Markus Tölle

Erschienen in: CardioVasc | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Patienten mit therapieresistenter arterieller Hypertonie (TRAH) sind oft eine Herausforderung in der alltäglichen Praxis. Mit der Etablierung interventioneller Verfahren, wie der renalen Denervation (RDN) und Barorezeptorstimulation (BRS), kam Hoffnung auf, den Blutdruck von fast allen TRAH-Patienten in den Zielbereich bringen zu können. Die letzte große RDN-Studie zeigte aber, dass ein gutes Studiendesign und adäquate Patientenselektion entscheidend sind, um die Bedeutung der RDN richtig einschätzen zu können.

Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–19CrossRefPubMed

Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19CrossRefPubMed

Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076–80CrossRefPubMed

Muntner P, Davis BR, Cushman WC et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014;64:1012–21.CrossRefPubMed

Egan BM, Zhao Y, Axon RN et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046–58CrossRefPubMedPubMedCentral

Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635–42CrossRefPubMedPubMedCentral

Bangalore S, Fayyad R, Laskey R et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med. 2014;127:71–81 e71CrossRefPubMed

Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014;28:463–8CrossRefPubMedPubMedCentral

Egan BM, Zhao Y, Li J et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62:691–7CrossRefPubMedPubMedCentral

10.

Brambilla G, Bombelli M, Seravalle G et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens. 2013;31:2018–24CrossRefPubMed

11.

Jung O, Gechter JL, Wunder C et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766–4CrossRefPubMed

12.

Lotufo PA, Pereira AC, Vasconcellos PS et al. Resistant hypertension: risk factors, subclinical atherosclerosis, and comorbidities among adults-the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Clin Hypertens (Greenwich) 2015;17:74–80CrossRef

13.

Esler M, Jennings G, Korner P et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988;11:3–20CrossRefPubMed

14.

DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75–197PubMed

15.

Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659–82PubMed

16.

Ewen S, Cremers B, Meyer MR et al. Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. J Hypertens. 2015;33:2519–25CrossRefPubMed

17.

Donazzan L, Mahfoud F, Ewen S et al. Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. Clin Res Cardiol. 2015 Oct 22. doi: 10.1007/s00392-015-0930-4

18.

Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81CrossRefPubMed

19.

Symplicity HTNI, Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9CrossRef

20.

Krum H, Schlaich MP, Sobotka PA et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622–9CrossRefPubMed

21.

Esler MD, Bohm M, Sievert H et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35:1752–9CrossRefPubMed

22.

Mahfoud F, Ukena C, Schmieder RE et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132–40CrossRefPubMed

23.

Bhatt DL, Kandzari DE, O’Neill WW et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401CrossRefPubMed

24.

Tzafriri AR, Keating JH, Markham PM et al. Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension. Sci Transl Med 2015;7:285ra265CrossRef

25.

Amsterdam WA, Blankestijn PJ, Goldschmeding R, Bleys RL. The morphological substrate for Renal Denervation: nerve distribution patterns and parasympathetic nerves. A post-mortem histological study. Ann Anat 2015;204:71–9CrossRefPubMed

26.

Mahfoud F, Tunev S, Ewen S et al. Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. J Am Coll Cardiol 2015;66:1766–75CrossRefPubMed

27.

Mahfoud F, Luscher TF, Andersson B et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149–57CrossRefPubMed

28.

Schlaich MP, Schmieder RE, Bakris G et al. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031–45CrossRefPubMed

29.

Rimoldi SF, Scheidegger N, Scherrer U et al. Anatomical eligibility of the renal vasculature for catheter-based renal denervation in hypertensive patients. JACC Cardiovasc Interv. 2014;7:187–92CrossRefPubMed

30.

Sakakura K, Ladich E, Cheng Q et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J AM Coll Cardiol. 2014;64:635–43CrossRefPubMed

31.

Id D, Kaltenbach B, Bertog SC et al. Does the presence of accessory renal arteries affect the efficacy of renal denervation? JACC Cardiovasc Interv. 2013;6:1085–91CrossRefPubMed

32.

Mauriello A, Rovella V, Anemona L et al. Increased Sympathetic Renal Innervation in Hemodialysis Patients Is the Anatomical Substrate of Sympathetic Hyperactivity in End-Stage Renal Disease. J Am Heart Assoc. 2015;4(12). doi: 10.1161/JAHA.115.002426

33.

Kim BK, Bohm M, Mahfoud F et al. Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea). J Hum Hypertens. 2015 Jul 9. doi: 10.1038/jhh.2015.77

34.

Kandzari DE, Bhatt DL, Brar S et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219–27CrossRefPubMedPubMedCentral

35.

James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20CrossRefPubMed

36.

Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33:1058–66CrossRefPubMed

37.

Grassi G, Seravalle G, Brambilla G et al. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. Int J Cardiol. 2014;177:1020–5CrossRefPubMed

38.

Ewen S, Ukena C, Linz D et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension. 2015;65:193–9CrossRefPubMed

39.

Grassi G, Seravalle G, Brambilla G et al. Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects. Hypertension. 2015;65:1209–16CrossRefPubMed

40.

Franklin SS, Gustin W 4th, Wong ND et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96:308–15CrossRefPubMed

41.

Muxfeldt ES, Salles GF. Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension? J Hypertens. 2008;26:878–84CrossRefPubMed

42.

Ott C, Schmid A, Toennes SW et al. Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. EuroIntervention. 2015;11:110–16CrossRefPubMed

43.

Reference Values for Arterial Stiffness’ Collaboration, Mattace-Raso F, Hofman A, Verwoert GC et al. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‚establishing normal and reference values’. Eur Heart J. 2010;31:2338–50CrossRef

44.

von Arx R, Rexhaj E, Allemann Y et al. Lack of blood pressure-lowering effect of renal denervation in a drug-naive patient with pronounced arterial stiffening. Am J Med. 2014;127:e3–4CrossRefPubMed

45.

Feldman R, Bacher M, Campbell N et al. Adherence to pharmacologic management of hypertension. Can J Public Health. 1998;89:I16–18PubMed

46.

Howard JP, Patel H, Shun-Shin MJ et al. Impact of number of prescribed medications on visit-to-visit variability of blood pressure: implications for design of future trials of renal denervation. J Hypertens. 2015;33:2359–67CrossRefPubMed

47.

Ewen S, Meyer MR, Cremers B et al. Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol. 2015;104:1097–105CrossRefPubMed

48.

Kario K, Bhatt DL, Brar S et al. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015;66:1130–37PubMed

49.

Mahfoud F, Edelman ER, Bohm M. Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol. 2014;64:644–6CrossRefPubMed

50.

Mahfoud F, Luscher TF. Renal denervation: symply trapped by complexity? Eur Heart J. 2015;36:199–202CrossRefPubMed

51.

Azizi M, Sapoval M, Gosse P et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385:1957–65CrossRefPubMed

52.

Papademetriou V, Tsioufis CP, Sinhal A et al. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Hypertension. 2014;64:565–72CrossRefPubMed

53.

Verheye S, Ormiston J, Bergmann MW et al. Twelve-month results of the rapid renal sympathetic denervation for resistant hypertension using the OneShotTM ablation system (RAPID) study. EuroIntervention. 2015;10:1221–9CrossRefPubMed

54.

Zeller T, Andersson B, Bohm M et al. The paradise renal denervation system: Initial clinical results from the achieve study. Euro-PCR. 2014;14A–OP205

55.

Shetty S, Belessing E, Roenschein U et al. Renal denervation using the novel therapeutic intra-vasculart ultrasound (tivus) catheter system - preliminary report of first-in-man safety and performance study. EuroPCR. 2014;14A–OP206

56.

Lohmeier TE, Irwin ED, Rossing MA et al. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004;43:306–11CrossRefPubMed

57.

Thrasher TN. Effects of chronic baroreceptor unloading on blood pressure in the dog. Am J Physiol Regul Integr Comp Physiol. 2005;288:R863–871CrossRefPubMed

58.

Lohmeier TE, Dwyer TM, Irwin ED et al. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension. 2007;49:1307–14CrossRefPubMed

59.

Heusser K, Tank J, Engeli S et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55:619–26CrossRefPubMed

60.

Wustmann K, Kucera JP, Scheffers I et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension. 2009;54:530–6CrossRefPubMed

61.

Lohmeier TE, Iliescu R, Liu B et al. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension. 2012;59:331–8CrossRefPubMedPubMedCentral

62.

Lohmeier TE, Liu B, Hildebrandt DA et al. Global- and renal-specific sympathoinhibition in aldosterone hypertension. Hypertension. 2015;65:1223–30CrossRefPubMed

63.

Lohmeier TE, Dwyer TM, Hildebrandt DA et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension. 2005;46:1194–200CrossRefPubMed

64.

Scheffers IJ, Kroon AA, Schmidli J et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56:1254–8CrossRefPubMed

65.

Ferguson GG, Eliasziw M, Barr HW et al. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. Stroke. 1999;30:1751–8CrossRefPubMed

66.

de Leeuw PW, Alnima T, Lovett E et al. Bilateral or unilateral stimulation for baroreflex activation therapy. Hypertension. 2015;65:187–92CrossRefPubMed

67.

Bakris GL, Nadim MK, Haller H et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6:152–8CrossRefPubMed

68.

Bisognano JD, Kaufman CL, Bach DS et al. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol. 2011;57:1787–8CrossRefPubMed

69.

Hoppe UC, Brandt MC, Wachter R et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6:270–6CrossRefPubMed

70.

Burchell AE, Lobo MD, Sulke N et al. Arteriovenous anastomosis: is this the way to control hypertension? Hypertension. 2014;64:6–12CrossRefPubMed

71.

Faul J, Schoors D, Brouwers S et al. Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. J Vasc Surg. 2014;59:1078–83CrossRefPubMed

72.

Lobo MD, Sobotka PA, Stanton A et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015;385:1634–41CrossRefPubMed

73.

Schmieder RE, Ott C, Lobo MD et al. Lb02.02: Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients with Isolated Systolic Hypertension Compared to Combined Hypertension. J Hypertens. 2015;33 Suppl 1:e85CrossRefPubMed

Titel: Lösung eines komplexen medizinischen Problems?
Interventionelle Verfahren bei therapieresistenter Hypertonie
verfasst von: Markus Tölle
Publikationsdatum: 10.03.2016
Verlag: Springer Medizin
Schlagwörter: Hypertonie
Hypertonie
Erschienen in: CardioVasc / Ausgabe 1/2016
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI: https://doi.org/10.1007/s15027-016-0823-0

Passend zum Thema

SGLT-2-Inhibitoren für alle Patient:innen mit chronischer Herzinsuffizienz empfohlen

Niere und Herz

Das ESC-Leitlinien-Update 2023 bedeutet einen Paradigmenwechsel in der Behandlung der Herzinsuffizienz (HF), denn nun werden SGLT-2i sowohl für HFrEF, als auch für HFmrEF und HFpEF empfohlen. Somit können jetzt alle Patient:innen mit HF von SGLT-2i als zentralem Bestandteil der Therapie profitieren.

Dapagliflozin als neue Therapieoption zur Behandlung einer Herzinsuffizienz unabhängig von der Ejektionsfraktion

Niere und Herz

Dapagliflozin ist nun zur Behandlung aller Patient:innen mit chronischer symptomatischer Herzinsuffizienz zugelassen und bietet somit auch neue Hoffnung für die Therapie von jenen mit HFpEF. In der DELIVER-Studie zeigte der SGLT-2-Inhibitor eine signifikante Reduktion von Herzinsuffizienz-Hospitalisierungen und CV-Todesfällen.

ACS-Erstlinientherapie: Konsensbeschluss rät zur DAPT mit Ticagrelor

Niere und Herz

Ein Konsortium führender Fachgesellschaften erarbeitete jüngst auf Basis umfangreicher Metaanalysen einen Konsens für die Therapie koronarer Herzkrankheiten. Was dabei auffiel: Die duale Plättchenhemmung (DAPT) mit Ticagrelor ist die bevorzugte Therapieoption für das akute Koronarsyndrom (ACS).

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Hypertonie: Neues Duo für die Initialtherapie

Digitaler Adhärenzhelfer motiviert den Patienten und entlastet den Arzt

Kathetervirtuosen im Münchner Haus der Kunst

Zentralen Blutdruck in die Therapie einbeziehen

„Verdicktes“ Herz: Sportler oder Patient?

Zentraler Blutdruck noch nicht reif für die Routine

Passend zum Thema

SGLT-2-Inhibitoren für alle Patient:innen mit chronischer Herzinsuffizienz empfohlen

Dapagliflozin als neue Therapieoption zur Behandlung einer Herzinsuffizienz unabhängig von der Ejektionsfraktion

ACS-Erstlinientherapie: Konsensbeschluss rät zur DAPT mit Ticagrelor